Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics has reported Cash from Financing Activities over the past 8 years, most recently at $274.5 million for Q3 2025.

  • Quarterly results put Cash from Financing Activities at $274.5 million for Q3 2025, up 92640.88% from a year ago — trailing twelve months through Sep 2025 was $314.9 million (up 49.19% YoY), and the annual figure for FY2024 was $255.6 million, up 91.37%.
  • Cash from Financing Activities for Q3 2025 was $274.5 million at Dianthus Therapeutics, up from $568000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for DNTH hit a ceiling of $274.5 million in Q3 2025 and a floor of -$4.9 million in Q4 2023.
  • Median Cash from Financing Activities over the past 4 years was $568000.0 (2025), compared with a mean of $69.2 million.
  • Peak annual rise in Cash from Financing Activities hit 92640.88% in 2025, while the deepest fall reached 99.93% in 2025.
  • Dianthus Therapeutics' Cash from Financing Activities stood at $96.6 million in 2022, then plummeted by 105.03% to -$4.9 million in 2023, then skyrocketed by 915.54% to $39.7 million in 2024, then surged by 591.89% to $274.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $274.5 million (Q3 2025), $568000.0 (Q2 2025), and $161000.0 (Q1 2025) per Business Quant data.